Oruka Therapeutics (ORKA) reported a Q4 net loss late Thursday of $0.49 per diluted share.
Analysts polled by FactSet expected a loss of $0.74.
Oruka did not provide revenue for the quarter and year-ago figures.
The company said its cash, cash equivalents and marketable securities at the end of 2024 were $394 million and are projected to fund the company through 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.